- Home
- NKGN vs CANF Comparison
NKGN vs CANF Comparison
Compare NKGN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKGN
- CANF
- Stock Information
- Founded
- NKGN 2017
- CANF 1994
- Country
- NKGN United States
- CANF Israel
- Employees
- NKGN N/A
- CANF N/A
- Industry
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- NKGN Health Care
- CANF Health Care
- Exchange
- NKGN Nasdaq
- CANF Nasdaq
- Market Cap
- NKGN 22.6M
- CANF 14.4M
- IPO Year
- NKGN N/A
- CANF N/A
- Fundamental
- Price
- NKGN $0.70
- CANF $1.52
- Analyst Decision
- NKGN
- CANF Strong Buy
- Analyst Count
- NKGN 0
- CANF 2
- Target Price
- NKGN N/A
- CANF $14.00
- AVG Volume (30 Days)
- NKGN 598.6K
- CANF 1.2M
- Earning Date
- NKGN 01-07-2025
- CANF 02-03-2025
- Dividend Yield
- NKGN N/A
- CANF N/A
- EPS Growth
- NKGN N/A
- CANF N/A
- EPS
- NKGN N/A
- CANF N/A
- Revenue
- NKGN N/A
- CANF $667,000.00
- Revenue This Year
- NKGN N/A
- CANF $409.56
- Revenue Next Year
- NKGN N/A
- CANF N/A
- P/E Ratio
- NKGN N/A
- CANF N/A
- Revenue Growth
- NKGN N/A
- CANF N/A
- 52 Week Low
- NKGN $0.20
- CANF $1.29
- 52 Week High
- NKGN $4.06
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- NKGN 64.89
- CANF 41.02
- Support Level
- NKGN $0.63
- CANF $1.41
- Resistance Level
- NKGN $0.97
- CANF $1.54
- Average True Range (ATR)
- NKGN 0.10
- CANF 0.10
- MACD
- NKGN 0.02
- CANF 0.02
- Stochastic Oscillator
- NKGN 57.18
- CANF 52.38
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).